Amplify Weight Loss Drug & Treatment ETF (THNR)

Assets	$4.74M
Expense Ratio	0.59%
PE Ratio	30.07
Shares Out	180,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	n/a

Volume	9,277
Open	26.48
Previous Close	26.57
Day's Range	26.18 - 26.48
52-Week Low	24.92
52-Week High	28.19
Beta	n/a
Holdings	31
Inception Date	May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NYSEARCA
• Ticker Symbol: THNR
• ETF Provider: Amplify Investments
• Index Tracked: VettaFi Weight Loss Drug Index

Top 10 Holdings

68.85% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	15.26%
Novo Nordisk A/S	NVO	13.43%
Roche Holding AG	ROG	5.31%
Pfizer Inc.	PFE	5.19%
AstraZeneca PLC	AZN	5.13%
Thermo Fisher Scientific Inc.	TMO	5.08%
Amgen Inc.	AMGN	5.05%
Merck & Co., Inc.	MRK	4.89%
Chugai Pharmaceutical Co., Ltd.	4519	4.83%
FUJIFILM Holdings Corporation	4901	4.68%